DermTech, Inc.

DermTech, Inc. operates as a molecular diagnostics firm specializing in developing and commercializing innovative, non-invasive genomic tests designed to assist in the early detection and ongoing management of melanoma within the United States. Its flagship product, the DermTech Melanoma Test (DMT), offers a non-surgical method for improved melanoma detection, with further development underway for non-melanoma skin cancers. Complementing this, the DermTech Smart Sticker facilitates the non-invasive collection of skin samples, presenting a gentler alternative to traditional scalpel biopsies for suspicious lesions. Additionally, the company extends its expertise to pharmaceutical firms, offering contract research services and its proprietary technology platform for use in clinical trials. DermTech also creates gene expression assays targeting conditions like psoriasis, atopic dermatitis, and skin aging, aiding pharmaceutical partners in dermatological drug development and offering bespoke gene assay solutions. Its products are distributed primarily through pathology and oncology specialists. Headquartered in San Diego, California, DermTech, Inc. and an affiliated entity initiated voluntary Chapter 11 bankruptcy proceedings for reorganization in the U.S. Bankruptcy Court for the District of Delaware on June 18, 2024.